Abstract

A GLP-1 Receptor Agonist Looks Promising in Phase 2 Study for Parkinson's Disease

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call